Navigation Links
Webcast Alert: Cytomedix Inc (GTF) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation
Date:7/15/2010

NEW YORK, July 15 /PRNewswire-FirstCall/ -- Cytomedix Inc (GTF) announces the following Webcast:

What:  LHA Life Sciences & Med Tech Day 2010 Presentation

When:  July 20, 2010 @ 9:00 AM Eastern

Where:  http://www.investorcalendar.com/ClientPage.asp?ID=160316

How:  Live over the Internet -- Simply log on to the web at the address above.

Contact:  Cheryl Palazzo, 212-838-3777, cpalazzo@lhai.com

If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=160316 or http://www.investorcalendar.com/

Cytomedix, Inc. (NYSE Amex: GTF)  Cytomedix is a biotechnology company that develops, sells, and licenses regenerative biological therapies, to primarily address the areas of wound care, inflammation, and angiogenesis. The Company currently markets the AutoloGel™ System, a device for the production of platelet rich plasma ("PRP") gel derived from the patient's own blood for use on a variety of exuding wounds; the Angel® Whole Blood Separation System, a blood processing device and disposable products used for separation of whole blood into red cells, platelet poor plasma and platelet rich plasma ("PRP") in surgical settings; and the activAT® Autologous Thrombin Processing Kit, which produces autologous thrombin serum from platelet poor plasma.  The activAT® kit is sold exclusively in Europe and Canada, where it provides a completely autologous, safe alternative to bovine-derived products. The Company is currently pursuing a multi-faceted strategy to penetrate the chronic wound market with its products. Cytomedix is also pursuing opportunities for the application of AutoloGel™ and PRP technology into other markets such as hair transplantation and orthopedics, as well as actively seeking complementary products for the wound care market. The Company also seeks to monetize other product candidates in its pipeline through strategic partnerships, out-licensing, or sale. Most notably is its anti-inflammatory peptide (designated "CT-112") that has shown promise in pre-clinical testing. Additional information regarding Cytomedix is available at www.cytomedix.com.


'/>"/>
SOURCE Cytomedix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Webcast Alert: Senesco Technologies (SNT) Announces the LHA Life Sciences & Med Tech Day 2010 Presentation
2. Angiotech Pharmaceuticals Announces Conference Call and Webcast
3. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
4. Caliper Life Sciences to Webcast Investor Session of Open House
5. Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
6. BioMed Realty Trust to Webcast Company Presentation at Investor Day 2010
7. Resverlogix Notice of Conference Call & Webcast for Year End Update
8. Advanced Life Sciences to Host 2010 First Quarter Financial Results Conference Call and Webcast
9. Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
10. Volcano Corporation Schedules First Quarter Conference Call, Webcast
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... ... be safely completed in an ambulatory surgery center (ASC) with satisfactory clinical and ... previous two-year TDR studies. , Jake Lubinski, president of AxioMed, commented on ...
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by ... biotechnology are now the fastest growing categories, finds ... Specialty Actives in Personal Care: Multi-regional Market Analysis ... and management consulting firm Kline. "Biotechnology ... that make them more effective for skin and ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
Breaking Biology Technology:
(Date:2/14/2017)...  Wake Forest Baptist Medical Center today announced Julie Ann ... officer (CEO). Freischlag joins the medical center on May ... M.D., who last year announced that he would transition ... leading it since 2008.   As CEO, ... Baptist,s academic health system, which includes Wake Forest School ...
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
Breaking Biology News(10 mins):